Driving drug development forward with precision genomics
Mission Statement
The current landscape of preclinical drug development is plagued by slow progress, soaring costs, and a frustratingly high rate of failure. At CellCipher, we believe we can break this cycle and create a more effective path for drug development by improving the predictive power of preclinical toxicity testing and by enabling precision medicine for clinical trials.
Our Approach
Ethical and efficient human in vitro models
Using models that are scalable, robust, and sustainable, CellCipher is exploring uncharted territories in pharmacogenomics. Our streamlined in vitro experiments capture data from a multitude of human cell types, which we mine to extract meaningful biological insights that can accelerate the pace of drug development while reducing the need for animal testing.
Single-cell genomics
Single-cell genomics allows us to study cellular heterogeneity and function within complex biological systems. By measuring drug-induced transcriptional outcomes in a broad array of human cell types, we can construct whole-body response profiles to infer underlying drug mechanisms and assess safety.
Population-scale data
Treatment responses can vary based on genetic makeup. We are paving a path toward equity in precision medicine by integrating dynamic, context-specific genomic data with genetic information from diverse individuals.
Improved prediction
Our cutting-edge machine learning models are trained on high-dimensional molecular data captured from disease-relevant cell types and drug-specific contexts, enabling better prediction of individual drug responses. We are also developing models that can facilitate target discovery, identify genetic biomarkers of toxicity and efficacy, and repurpose existing drugs.
